Literature DB >> 1485374

A liquid chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma.

A Fazio1, C Artesi, M Russo, R Trio, G Oteri, F Pisani.   

Abstract

A sensitive, specific and rapid liquid-chromatographic method for the determination of the new antiepileptic drug lamotrigine (LTG) in human plasma is described. The method involves the use of a commercially available 3-microns particle size normal-phase column and a microflow-cell-equipped ultraviolet detector. Extraction is carried out with ethyl acetate after alkalinization on a 100-microliters plasma sample containing LTG and 3,5-diamino-6-(2-methoxyphenyl)-1,2,4-triazine as internal standard. The residue is reconstituted with 50 microliters of ethanol, and 5 microliters of the final solution is injected into the column. Elution is carried out at 35 degrees C using n-hexane/absolute ethanol/35% ammonia (80/20/0.25 by volume) as mobile phase at a flow rate of 2.0 ml/min. Detection is at 313 nm. The chromatographic separation requires < 3 min and the sensitivity limit is < 0.1 mg/L. Recovery is 88-96.2%, whereas within-day and day-to-day coefficients of variation are between 4.1 and 7.7%.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1485374     DOI: 10.1097/00007691-199212000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry.

Authors:  Woonhyoung Lee; Jeong-Ho Kim; Hyon-Suk Kim; Oh Hun Kwon; Byung In Lee; Kyoung Heo
Journal:  Neurol Sci       Date:  2010-12       Impact factor: 3.307

Review 2.  Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Authors:  K L Goa; S R Ross; P Chrisp
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 3.  Lamotrigine clinical pharmacokinetics.

Authors:  B Rambeck; P Wolf
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.